Skip to main content
L

Lionco Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 603669 ISIN · CNE1000022R8 LEI · 300300EU7LBPZ25TZO93 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,201 across all filing types
Latest filing 2025-09-22 Governance Information
Country CN China
Listing Shanghai Stock Exchange 603669

About Lionco Pharmaceutical Group Co.,Ltd.

Lionco Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and sale of chemical drug preparations. The company specializes in a diverse range of therapeutic areas, including anti-infectives, digestive system treatments, cardiovascular health, and respiratory medicine. Its product portfolio primarily consists of high-end generic drugs, featuring formulations such as freeze-dried powder for injection, small-volume injections, and solid oral dosages. Lionco emphasizes technological innovation and quality control to provide clinical solutions for various medical conditions. The group operates multiple manufacturing facilities and maintains a comprehensive distribution network to serve healthcare providers and patients.

Recent filings

Filing Released Lang Actions
总经理工作细则（2025年9月修订）
Governance Information Classification · 95% confidence The document is titled '总经理工作细则' which translates to 'General Manager Work Rules' or 'General Manager Operating Procedures'. It outlines the qualifications, appointment procedures, responsibilities, and reporting requirements of the General Manager of the company. The content focuses on governance structure and management roles rather than financial data, earnings, or regulatory filings. It is a detailed governance document related to management roles and internal company rules. There is no indication that this is an announcement, a financial report, or a regulatory filing. Therefore, the document best fits the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-09-22 Chinese
投资者关系管理制度（2025年9月修订）
Governance Information Classification · 95% confidence The document is titled '投资者关系管理制度' which translates to 'Investor Relations Management System' and details the company's policies and procedures for managing investor relations, including communication with investors, compliance with laws and regulations, and organizational responsibilities. It does not contain financial statements, earnings data, or audit information. It is a governance-related document outlining internal rules and practices for investor relations management. Therefore, it fits best under Governance Information (CGR). The document length is 5660 characters, which is sufficient for a detailed policy document, not a brief announcement or a report publication notice.
2025-09-22 Chinese
董事会薪酬与考核委员会工作细则（2025年9月修订）
Governance Information Classification · 100% confidence The document is titled '董事会薪酬与考核委员会工作细则' which translates to 'Board Remuneration and Assessment Committee Working Rules'. It details the structure, responsibilities, composition, and procedures of the board committee responsible for remuneration and performance assessment of directors and senior management. It is a governance-related document outlining internal rules and policies rather than financial results, audit information, or announcements. There is no indication of financial data, voting results, or report publication. The content fits the definition of Governance Information (CGR), which covers internal rules, board structure, and governance practices.
2025-09-22 Chinese
关于召开2025年半年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the upcoming 2025 half-year performance explanation meeting (业绩说明会) for Lingkang Pharmaceutical Group Co., Ltd. It specifies the meeting date, time, location, participation method, and contact details. It references that the 2025 half-year report has already been disclosed on August 23, 2025, and this meeting is to facilitate investor understanding and interaction regarding that report. The document does not contain actual financial statements or detailed financial analysis but serves as a notice for the event where such information will be discussed. The document length is short (1315 characters), and it is clearly an announcement of a meeting related to the interim report, not the report itself or a transcript of the meeting. Therefore, it fits best into the category of Investor Presentation (IP) or possibly a Regulatory Filing (RNS). However, since it is specifically about an investor meeting to explain financial results, the best fit is Investor Presentation (IP).
2025-09-19 Chinese
2025年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '灵康药业集团股份有限公司2025 年半年度报告' which translates to 'Lingkang Pharmaceutical Group Co., Ltd. 2025 Semi-Annual Report'. It contains detailed financial data, management discussion and analysis, company overview, financial indicators, and operational details for the period January to June 2025. The length is substantial (15,000 characters), and it includes actual financial statements and substantive financial data. The content matches the characteristics of an Interim / Quarterly Report, which is a comprehensive financial report for a period shorter than a full fiscal year. There is no indication that this is merely an announcement or a certification document. Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2025
2025-08-22 Chinese
第四届监事会第二十次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 20th meeting of the 4th Supervisory Board of Lingkang Pharmaceutical Group Co., Ltd. It includes the Supervisory Board's review and approval of the company's 2025 semi-annual report and a special report on the use of raised funds. The document states that the detailed content of the semi-annual report and the special report are disclosed separately on the Shanghai Stock Exchange website, indicating this document is an announcement of meeting resolutions rather than the full semi-annual report itself. The document length is short (951 characters), and it primarily reports on the meeting and voting results. This fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about supervisory board resolutions and report approvals, not the report itself or a detailed financial report.
2025-08-22 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.